ASRock is expanding beyond motherboards and GPUs into the all-in-one liquid cooling market. Its new lineup includes a pumpless design that moves the pump away from the CPU block, plus standard models with LCD displays.
A new report details Samsung’s 2025 roadmap, claiming the Galaxy S26 series will launch February 25 in San Francisco. Surprisingly, prices may hold steady. Lighter foldables are coming in July.
The annual tech forecast is out, and it’s not about the latest AI chatbot. It’s about physical, tangible engineering solving massive problems. From compressing CO2 in giant domes to using radio waves inside servers, the ideas are brilliantly weird.
Samsung is shaking up its supply chain for its upcoming mid-range phone. The Galaxy A57 will reportedly feature a flexible OLED display, sourced in part from Chinese manufacturer CSOT.
Digital wallets have evolved from simple payment tools to the primary interface for global money movement. New data shows they’re now used for nearly two-thirds of U.S. consumer cross-border payments, with adoption spreading across all age groups.
According to Forbes, AI is moving from writing emails to running factories. A startup called Forgis is layering AI agents on old machinery to make manufacturing smarter and more efficient, with a bold goal of helping to onshore production.
According to Reuters, the most-read financial analysis of 2025 centered on geopolitical risk and corporate intrigue. Readers on trading terminals feared a shifting global order, while website subscribers were gripped by stories from BYD to hedge funds.
Samsung announced its Exynos Modem 5410 can make native satellite voice calls, a first for smartphones. But the feature will likely be limited to South Korea and won’t be on the flagship S26 Ultra at all, creating a weird feature gap.
New research reveals a staggering 82:1 ratio of machine to human identities, with AI agents as the wild card. Legacy identity systems, built for people, are breaking down at machine speed, creating massive security blind spots.
Insilico Medicine, an AI drug discovery startup, saw its shares surge 25% on its first day of trading in Hong Kong. The $293 million IPO caps a year of intense investor interest in Chinese biotech and AI. The company plans to scale its drug discovery efforts and develop new AI models with the fresh
